NR 566 Week 1 Midterm Exam | Latest Update
2026/2027 | 200 Practice Questions & Detailed Answers
| Actual Exam Screenshots with Complete Solutions |
A+ Graded
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS (Questions 1–50)
1. Which process describes what the body does to a drug, including absorption, distribution,
metabolism, and excretion?
A) Pharmacodynamics
B) Pharmacokinetics
C) Pharmacogenomics
D) Pharmacotherapeutics
Answer: B
Explanation: Pharmacokinetics describes what the body does to a drug, encompassing absorption,
distribution, metabolism, and excretion. Pharmacodynamics describes what the drug does to the body.
2. A drug exhibits a volume of distribution (Vd) of 500 L and a clearance (Cl) of 50 L/hr. Assuming
firstorder elimination, what is the elimination halflife (t½) of this drug?
A) 3.5 hours
B) 5.0 hours
C) 6.9 hours
D) 10.0 hours
Answer: C
,Explanation: Halflife is calculated as t½ = 0.693 × Vd / Cl. Here, t½ = 0.693 × = 6.93 hours,
approximately 6.9 hours.
3. A drug with a narrow therapeutic index is administered orally. Which scenario would most likely result
in a subtherapeutic response if the drug follows firstorder kinetics and has high firstpass metabolism?
A) Concomitant administration with a drug that induces CYP3A4
B) Administration with a highfat meal that increases gastric emptying
C) Chronic use of a proton pump inhibitor that raises gastric pH
D) Coadministration with a drug that inhibits Pglycoprotein in the gut
Answer: A
Explanation: Induction of CYP3A4 increases firstpass metabolism, reducing bioavailability and potentially
leading to subtherapeutic levels. Pgp inhibition typically increases absorption, not decreases.
4. A patient with chronic kidney disease (CKD) stage 4 is prescribed a drug that is primarily eliminated
unchanged by the kidneys. Which pharmacokinetic parameter is most likely to be significantly altered,
requiring dose adjustment?
A) Bioavailability
B) Volume of distribution
C) Clearance
D) Peak concentration
Answer: C
Explanation: In CKD, renal clearance of drugs eliminated unchanged by the kidneys is significantly
reduced, leading to drug accumulation and requiring dose adjustment.
,5. Which phase of pharmacokinetics is most significantly affected by a patient's genetic polymorphism of
the CYP450 enzyme system?
A) Absorption
B) Metabolism
C) Distribution
D) Excretion
Answer: B
Explanation: Metabolism is the primary phase affected by CYP450 enzymes. Genetic polymorphisms can
lead to ultrarapid, extensive, intermediate, or poor metabolism of drugs, impacting efficacy and toxicity.
6. What is the primary mechanism of firstpass metabolism?
A) Drug metabolism in the kidneys before reaching systemic circulation
B) Drug metabolism in the liver and gut wall before reaching systemic circulation
C) Drug metabolism in the lungs after intravenous administration
D) Drug metabolism in the brain after crossing the bloodbrain barrier
Answer: B
Explanation: Firstpass metabolism refers to the metabolism of a drug in the liver and gut wall before it
reaches systemic circulation, significantly reducing bioavailability of orally administered drugs.
7. Which route of administration bypasses firstpass metabolism?
A) Oral
B) Rectal
C) Sublingual
, D) Enteral
Answer: C
Explanation: Sublingual administration bypasses firstpass metabolism because the drug is absorbed
directly into the systemic circulation through the venous drainage of the oral mucosa.
8. What is the primary determinant of drug distribution?
A) Drug metabolism rate
B) Protein binding and lipid solubility
C) Renal clearance
D) Hepatic blood flow
Answer: B
Explanation: Drug distribution is primarily determined by protein binding and lipid solubility, which
affect how the drug moves from the bloodstream into tissues.
9. A patient with hypoalbuminemia is at increased risk for which drugrelated complication?
A) Reduced drug efficacy
B) Increased drug toxicity
C) Faster drug excretion
D) Decreased drug absorption
Answer: B
Explanation: Hypoalbuminemia reduces protein binding sites, increasing the free (unbound) fraction of
highly proteinbound drugs, which can lead to increased drug effect and toxicity.
2026/2027 | 200 Practice Questions & Detailed Answers
| Actual Exam Screenshots with Complete Solutions |
A+ Graded
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS (Questions 1–50)
1. Which process describes what the body does to a drug, including absorption, distribution,
metabolism, and excretion?
A) Pharmacodynamics
B) Pharmacokinetics
C) Pharmacogenomics
D) Pharmacotherapeutics
Answer: B
Explanation: Pharmacokinetics describes what the body does to a drug, encompassing absorption,
distribution, metabolism, and excretion. Pharmacodynamics describes what the drug does to the body.
2. A drug exhibits a volume of distribution (Vd) of 500 L and a clearance (Cl) of 50 L/hr. Assuming
firstorder elimination, what is the elimination halflife (t½) of this drug?
A) 3.5 hours
B) 5.0 hours
C) 6.9 hours
D) 10.0 hours
Answer: C
,Explanation: Halflife is calculated as t½ = 0.693 × Vd / Cl. Here, t½ = 0.693 × = 6.93 hours,
approximately 6.9 hours.
3. A drug with a narrow therapeutic index is administered orally. Which scenario would most likely result
in a subtherapeutic response if the drug follows firstorder kinetics and has high firstpass metabolism?
A) Concomitant administration with a drug that induces CYP3A4
B) Administration with a highfat meal that increases gastric emptying
C) Chronic use of a proton pump inhibitor that raises gastric pH
D) Coadministration with a drug that inhibits Pglycoprotein in the gut
Answer: A
Explanation: Induction of CYP3A4 increases firstpass metabolism, reducing bioavailability and potentially
leading to subtherapeutic levels. Pgp inhibition typically increases absorption, not decreases.
4. A patient with chronic kidney disease (CKD) stage 4 is prescribed a drug that is primarily eliminated
unchanged by the kidneys. Which pharmacokinetic parameter is most likely to be significantly altered,
requiring dose adjustment?
A) Bioavailability
B) Volume of distribution
C) Clearance
D) Peak concentration
Answer: C
Explanation: In CKD, renal clearance of drugs eliminated unchanged by the kidneys is significantly
reduced, leading to drug accumulation and requiring dose adjustment.
,5. Which phase of pharmacokinetics is most significantly affected by a patient's genetic polymorphism of
the CYP450 enzyme system?
A) Absorption
B) Metabolism
C) Distribution
D) Excretion
Answer: B
Explanation: Metabolism is the primary phase affected by CYP450 enzymes. Genetic polymorphisms can
lead to ultrarapid, extensive, intermediate, or poor metabolism of drugs, impacting efficacy and toxicity.
6. What is the primary mechanism of firstpass metabolism?
A) Drug metabolism in the kidneys before reaching systemic circulation
B) Drug metabolism in the liver and gut wall before reaching systemic circulation
C) Drug metabolism in the lungs after intravenous administration
D) Drug metabolism in the brain after crossing the bloodbrain barrier
Answer: B
Explanation: Firstpass metabolism refers to the metabolism of a drug in the liver and gut wall before it
reaches systemic circulation, significantly reducing bioavailability of orally administered drugs.
7. Which route of administration bypasses firstpass metabolism?
A) Oral
B) Rectal
C) Sublingual
, D) Enteral
Answer: C
Explanation: Sublingual administration bypasses firstpass metabolism because the drug is absorbed
directly into the systemic circulation through the venous drainage of the oral mucosa.
8. What is the primary determinant of drug distribution?
A) Drug metabolism rate
B) Protein binding and lipid solubility
C) Renal clearance
D) Hepatic blood flow
Answer: B
Explanation: Drug distribution is primarily determined by protein binding and lipid solubility, which
affect how the drug moves from the bloodstream into tissues.
9. A patient with hypoalbuminemia is at increased risk for which drugrelated complication?
A) Reduced drug efficacy
B) Increased drug toxicity
C) Faster drug excretion
D) Decreased drug absorption
Answer: B
Explanation: Hypoalbuminemia reduces protein binding sites, increasing the free (unbound) fraction of
highly proteinbound drugs, which can lead to increased drug effect and toxicity.
